What Is Lung Adenocarcinoma?
Lung adenocarcinoma is a very common lung cancer type, making up about 40% of all cases in the United States. It falls under non-small cell lung cancer (NSCLC) and is often diagnosed in people who have never smoked. Although treatments are improving, lung cancer remains the leading cause of cancer death in the United States, with an estimated 226,650 new cases and 124,730 deaths expected in 2025. Early symptom recognition and prompt diagnosis are critical for better outcomes.
Lung adenocarcinoma starts in the gland-like cells that line the alveoli, the tiny air sacs in the lungs where oxygen exchange takes place. Unlike some other types of lung cancer that grow near the main airways, it usually develops in the outer parts of the lungs. Because of this location, it does not tend to block the airways early, which is why symptoms often appear only in later stages.
The cancer is classified into four types: adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), invasive adenocarcinoma, and variants. AIS and MIA have better outcomes when resected early.
Symptoms of Lung Adenocarcinoma
The earliest stages are often asymptomatic, with nodules found incidentally on radiographic images taken for other reasons. When symptoms do appear, they are easy to confuse with common respiratory illnesses, which frequently delays diagnosis.
Common symptoms include:
- A persistent cough that does not improve
- Chest pain, mainly when breathing deeply or coughing
- Shortness of breath or wheezing
- Coughing up blood or blood-tinged phlegm
- Unexplained fatigue
- Loss of appetite and unintentional weight loss
- Hoarse or raspy voice
- Recurring chest infections
In more advanced cases, the cancer can cause symptoms from local spread, including facial swelling from vein compression, drooping eyelid (Horner's syndrome), or arm and shoulder pain from nerve involvement. Anyone with a persistent cough, unexplained weight loss, or blood in phlegm, especially with a smoking or asbestos exposure history, should see a doctor promptly.
Risk Factors
The biggest risk factor for lung cancer, including adenocarcinoma, is tobacco smoking. This includes both direct smoking and exposure to secondhand smoke, with the risk increasing the longer and more heavily a person is exposed.
Other key risk factors include:
- Asbestos and Radon: Occupational or environmental exposure significantly raises risk
- Secondhand Smoke: Raises risk even in people who have never smoked
- Air Pollution: Long-term exposure to diesel fumes, fine particles, and industrial pollutants
- Family History: Having a close relative with lung cancer can nearly double your risk
- Sex: Some research suggests women may be more prone to adenocarcinoma than men
- Genetic Mutations: Mutations in EGFR, ALK, ROS1, and KRAS genes are particularly common in lung adenocarcinoma and carry treatment implications
Diagnosis
Diagnosis begins with a physical examination and review of medical and smoking history, followed by imaging and laboratory testing. A lung biopsy is the only definitive confirmation of diagnosis.
Common diagnostic tests include:
- Low-dose CT (LDCT) scan: This is the recommended screening test for people at high risk. It can help detect lung cancer early and has been shown to lower the risk of death by about 16-24% in these individuals.
- PET/CT scan: This scan looks at how active the cancer is and helps doctors see if it has spread to nearby lymph nodes or other body parts.
- Brain MRI: Often advised in more advanced stages (Stage II-IV) to check if the cancer has spread to the brain.
- Biopsy: Confirms malignancy and enables molecular testing for driver mutations
Molecular profiling of biopsy tissue, including EGFR, ALK, PD-L1, and other biomarkers, is now standard practice and directly determines the most effective treatment approach.
Treatment Options
Treatment is guided by cancer stage and the tumour's molecular profile. A multidisciplinary team typically makes treatment recommendations.
Surgery is the primary treatment for early-stage (I-IIIA) resectable disease. The removal of one lobe of the lung (Lobectomy) is the most common procedure. Adjuvant chemotherapy after surgery is now standard to reduce recurrence risk.
Chemotherapy using platinum-based drug combinations remains important for patients without targetable mutations and as adjuvant or palliative therapy.
Targeted therapy has transformed outcomes for adenocarcinoma patients with driver mutations. Tumours positive for EGFR may be treated with tyrosine kinase inhibitors, while those with the ALK mutation may be treated with ALK inhibitors as first-line therapy. These oral drugs are more effective and better tolerated than chemotherapy in mutation-positive patients.
Immunotherapy, particularly PD-1/PD-L1 checkpoint inhibitors, is used alone or combined with chemotherapy in advanced-stage patients, especially those with high PD-L1 expression without actionable driver mutations.
Radiation therapy is used when surgery is not possible, as a palliative measure for symptom relief, or to treat brain and bone metastases.
Survival Rate for Lung Adenocarcinoma
Survival rates have been improving. The overall 5-year survival rate for lung cancer has risen to 27% in 2025, compared to 17% in 2014, reflecting advances in screening, targeted therapy, and immunotherapy. Lung adenocarcinoma tends to carry a slightly better prognosis than other lung cancer subtypes overall.
5-year survival rates for NSCLC by stage (American Cancer Society):
People with adenocarcinoma in situ and minimally invasive adenocarcinoma have a better outcome, especially when treated early with surgery. If surgery completely removes the cancer, the 5-year survival rate approaches 100%. Survival rates are population-based estimates and do not reflect individual circumstances, molecular profile, or the latest treatment advances.
A 2025 study found that the median overall survival in patients diagnosed with lung adenocarcinoma more than doubled in 20 years, from 8.5 months in year 2000 to 20.7 months in year 2020, demonstrating the real-world impact of modern treatments.
Conclusion
Lung adenocarcinoma is a serious condition, but treatment options have improved significantly, especially when it is detected early. New advances such as low-dose CT scans, molecular testing, targeted therapies, and immunotherapy have helped many people do better. The most important steps are to stay proactive, avoid or quit smoking, limit exposure to harmful substances, pay attention to ongoing breathing problems, and get screened if you are at higher risk. For anyone diagnosed, specialist care at a comprehensive cancer centre, including molecular profiling and access to the latest treatments, offers the best possible chance of a good outcome.
